ARA 290 (Cibinetide)
Also known as: PHβSP, Innate Repair Receptor agonist
ARA 290 (Cibinetide), also called PHβSP or Innate Repair Receptor agonist, is an innate Repair Receptor agonist. ARA 290, also called cibinetide, is an eleven-amino-acid peptide corresponding to a helix B surface region of erythropoietin.
For research use only.
Key Facts
- CAS
- 1208243-63-3
- Molecular Weight (MW)
- 1257.3 g/mol
- Half-life
- Short plasma half life (reported minutes; tissue protective signaling persists longer in models)
- FDA status
- Investigational New Drug (IND)
- Administration Route
- Subcutaneous (most common in clinical trials)
- Frequency
- Once daily in many investigational studies
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Innate repair receptor (EPOR–βc)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 10
- Listed offers
- 11
- Median price per mg
- $5.00/mg
- Typical $4.75–$6.06/mg
Research summary
Helix-B surface peptide (cibinetide) that selectively activates the innate repair receptor without stimulating erythropoiesis. Investigational for small-fiber neuropathy and sarcoidosis.
Peptide Library's ARA 290 (Cibinetide) profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Dose dependent on clinical protocol; not established for general use
- Frequency
- Once daily in many investigational studies
- Cycle
- Investigational protocols vary; not established for consumer use
- Administration Route
- Subcutaneous (most common in clinical trials)
- Reconstitution Guide
- Reconstitute per supplier or clinical protocol instructions
- Injection Sites
- Abdomen (subQ)Thigh (subQ)
- Concentration Example
- Example only: 4 mg vial reconstituted with 2 mL = 2 mg/mL
- Expected Onset
- Tissue protective signaling observed in preclinical and early clinical studies
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. ARA 290 (Cibinetide) is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Amino acid sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
|---|---|
| Molecular formula | C51H84N16O21 |
| Molecular weight | 1257.3 g/mol |
| CAS number | 1208243-63-3 |
| Half-life | Short plasma half life (reported minutes; tissue protective signaling persists longer in models) |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
| PubChem CID | 91810664 |
| FDA UNII | 9W5677JKDA |
| ChEMBL | CHEMBL3545305 |
| DrugBank | DB13006 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
ARA 290, also called cibinetide, is an eleven-amino-acid peptide corresponding to a helix B surface region of erythropoietin. Erythropoietin has two distinct activities: haematopoiesis through the classical EPO receptor homodimer, and tissue protection through a separate heterodimeric innate repair receptor formed by EPOR paired with the beta common receptor CD131. ARA 290 was designed to engage only the second. It binds the innate repair receptor to trigger anti-inflammatory and cytoprotective signalling without stimulating erythropoiesis, avoiding the thrombotic and haematocrit effects that limit EPO itself. It has been studied in small-fibre neuropathy and sarcoidosis and is investigational.
Origin
Synthetic EPO helix-B peptide.
Targets
Studies
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes
- The time to develop treatments for diabetic neuropathy
- Managing fatigue in sarcoidosis - A systematic review of the evidence
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis
Regulatory & research status
ARA 290 (Cibinetide) has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Clinical Trial |
Benefits
ARA 290 (Cibinetide) side effects
Side Effects
- Injection-site reactions
- Headache
- Trial-stage safety only
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
ARA 290 (Cibinetide): frequently asked questions
What is ARA 290 (Cibinetide)?
Helix-B surface peptide (cibinetide) that selectively activates the innate repair receptor without stimulating erythropoiesis. Investigational for small-fiber neuropathy and sarcoidosis.
How does ARA 290 (Cibinetide) work?
ARA 290, also called cibinetide, is an eleven-amino-acid peptide corresponding to a helix B surface region of erythropoietin. Erythropoietin has two distinct activities: haematopoiesis through the classical EPO receptor homodimer, and tissue protection through a separate heterodimeric innate repair receptor formed by EPOR paired with the beta common receptor CD131.
Is ARA 290 (Cibinetide) FDA approved?
No. ARA 290 (Cibinetide) is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What is the half-life of ARA 290 (Cibinetide)?
Reported half-life for ARA 290 (Cibinetide) is Short plasma half life (reported minutes; tissue protective signaling persists longer in models). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of ARA 290 (Cibinetide)?
ARA 290 (Cibinetide) has the sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, giving a chain of 11 amino acids. Its molecular formula is C51H84N16O21.
What peptides are similar to ARA 290 (Cibinetide)?
Compounds most often compared with ARA 290 (Cibinetide) include Atosiban, B7-33, Carbetocin and Serelaxin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Invest Ophthalmol Vis Sci, 2017External reference
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Mol Med, 2015External reference
- The time to develop treatments for diabetic neuropathy — Expert Opin Investig Drugs, 2021External reference
- Managing fatigue in sarcoidosis - A systematic review of the evidence — Chron Respir Dis, 2017External reference
- ARA 290 for treatment of small fiber neuropathy in sarcoidosis — Expert Opin Investig Drugs, 2014External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This ARA 290 (Cibinetide) profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track ARA 290 (Cibinetide) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →